As of 2026-03-31, the Fair Value of Cardiff Oncology Inc (CRDF) is -3.35 USD. This value is based on the Peter Lynch's Fair Value formula. With the current market price of 1.55 USD, the upside of Cardiff Oncology Inc is -316.36%.
With the market price of 1.55 USD and our fair value calculation, Cardiff Oncology Inc (CRDF) is not a good investment. Investing in Cardiff stocks now will result in a potential loss of 316.36%.
Note: valuation result may not be accurate due to the company's negative EPS.
Peter Lynch's formula is:
The earnings growth rate we use in the formula is the average growth rate of net income/earnings over the last 5 years. If the average growth rate is smaller than 5%, we set it to 5%. If it is larger than 25%, we set it to 25%. If the TTM EPS is negative, Peter Lynch Fair Value's result can be unreliable.
| Historical Earnings | ||||||
| 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | 5Y Avg | |
| Net income | -28.29 | -38.70 | -41.44 | -45.43 | -45.85 | -39.94 |
| YoY growth | -46.50% | -36.80% | -7.08% | -9.63% | -0.92% | -20.19% |
| Market Cap (mil) | 105.96 |
| P/E | |
| Forward P/E |
| EPS | -0.67 |
| Avg earnings growth rate | -20.19% |
| TTM earnings | -45.85 |